Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 30.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 30.0 Contact Hours.

Mini Symposium: Designated for a maximum of 3.75 AMA PRA Category 1 Credits™ (3.75 Contact Hours)

Main Symposium: Designated for a maximum of 26.25 AMA PRA Category 1 Credits™ (26.25 Contact Hours)

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit www.absurgery.org/
default.jsp?exam-moccme

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, Puma Biotechnology, Inc, and TESARO, Inc.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

33rd Annual Miami Breast Cancer Conference®

33rd Annual Miami Breast Cancer Conference®


Thursday, March 10, 2016
7:30 PM - 9:00 PM


A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer Patients
Fontainebleau Miami Beach (Fontaine/ Fleur de Lis)
Independent CME-Certified Ancillary Satellite Symposium

 

Saturday, March 12, 2016
7:00 AM - 8:30 AM


Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers
Fontainebleau Miami Beach (Fontaine/ Fleur de Lis)
Independent CME-Certified Ancillary Satellite Symposium




A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer Patients

Thursday, March 10, 2016
7:30 PM - 9:00 PM
Fontainebleau Miami Beach (Fontaine/ Fleur de Lis)

Overview

A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer Patients is a live, continuing medical education (CME)-certified symposium, to be held adjunct to the 33rd Annual Miami Breast Cancer Conference®.

Optimization of pain control is a cornerstone of care in the surgical breast cancer patient. Multimodal approaches to analgesia are aimed at reducing pain and opioid use, and require multidisciplinary participation by the team in all phases of care, including pre-, peri-, and postsurgical settings. Uncontrolled acute postoperative pain can lengthen time in post-anesthesia care unit (PACU) and hospital, increase readmission and patient dissatisfaction, reduce quality of life, and place patients at increased risk for chronic pain. Although opioids have been a long-standing standard for pain control, they are associated with pruritus, nausea and vomiting, constipation, urinary retention, respiratory complications, and other chronic ailments. Many of these risks are modifiable through modern pharmacologic intervention, thorough planning, and effective communication and coordination across the care team.

This program will focus on state-of-the-art multimodal pain control strategies throughout the perioperative period, including methods to reduce opioid requirements, immediate-release and liposome-encapsulated local anesthetics, regional blocks, and best practices for administration of surgical analgesia strategies.

This CME symposium brings together a panel of internationally recognized experts in pain control to discuss how modern methodologies can be employed to effectively control pain while minimizing short- and long-term adverse sequelae of surgery, pain, and analgesia. The symposium is designed to be interactive between the audience and the faculty to promote interdisciplinary discussion around challenging situations that exist in real-world surgical practice settings.

Key areas of focus for this activity include:

  • A pathophysiological approach to pain types and pathways aligned with analgesic mechanisms
  • Goals for pain control in the pre-, intra-, and postoperative settings
  • Strategies for successful multimodal pain management and coordination of care
  • Assessment of opioid versus nonopioid strategies
  • Proactive management of opioid-associated adverse events
  • State-of-the-art pain control
  • Impact of pain control on outcomes
  • Interdisciplinary differences in pain control preferences and strategies

The symposium will be held at the Fontainebleau Miami Beach, on March 10, from 7:30 pm-9:00 pm. Please join us in Miami to learn how recent advances in multimodal perioperative pain control in breast cancer will impact patient treatment and management.

This will be the only independent CME-certified symposium focused entirely on surgical pain control for breast cancer. You won’t want to miss this activity!

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:
  • Explain the rationale for optimizing pain control in the surgical patient and the impact of uncontrolled postoperative pain
  • Define the goals of multimodal analgesia and the phases of care for which these strategies should be applied in surgical settings for patients with breast cancer
  • Discuss the benefits of opioid-sparing treatment regimens in the care of patients experiencing postsurgical pain
  • Apply best practices pertaining to the administration of pain control interventions in preoperative, intraoperative, and postoperative settings in caring for patients with breast cancer

Target Audience

This activity is intended for all attendees of the Miami Breast Cancer Conference® including medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also attend.

Chair

Patrick I. Borgen, MD
Chair, Department of Surgery
Maimonides Medical Center
Brooklyn, NY
 


Faculty

Jeff Gadsden, MD, FRCPC, FANZCA
Associate Professor
Department of Anesthesiology
Duke University Medical Center
Chapel Hill, NC

 

Donna-Marie Manasseh, MD
Director of Breast Surgery
Maimonides Breast Cancer Center
Brooklyn, NY


Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide CME for physicians.

Physicians' Education Resource, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pacira Pharmaceuticals, Inc.




Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers
Saturday, March 12, 2016
7:00 AM - 8:30 AM
Fontainebleau Miami Beach (Fontaine/ Fleur de Lis)

Overview

"Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers" is a live continuing medical education (CME)-certified symposium to be held adjunct to the 33rd Annual Miami Breast Cancer Conference®.

Treatment of estrogen receptor–positive (ER+), human epidermal growth factor 2–negative (HER2-), metastatic breast cancer remains an area of significant unmet clinical need. Efforts to improve upon the outcomes achieved with initial endocrine therapy have been largely unsuccessful, but active research into this area is expanding the arsenal of targeted therapies available for metastatic breast cancer. While novel therapies and combinations—such as a recently FDA-approved oral, highly selective CDK4/6 inhibitor—undeniably benefit patients with breast cancer, they also add markedly to the complexity of the treatment decision-making process. With the potential for broader indications of CDK4/6 inhibitory therapy in breast and other tumor types, these agents are likely to become more routinely used.

For this not-to-be-missed symposium, we are bringing together a panel of internationally recognized experts in breast cancer therapy to discuss how CDK4/6 inhibitors can advance the care of these patients, today and in the future. Faculty will cover key topics in the treatment of ER+, HER2-, metastatic breast cancer including:

  • Current perspectives on the management of these patients and unmet clinical needs
  • Overview of the CDKs in the cell cycle and as novel targets for drug development in breast cancer
  • Strategies for incorporating emerging efficacy and safety data from clinical trials of CDK4/6 inhibitory therapies into individualized treatment planning
    • Recognition and management of CDK inhibitor–related toxicities
    • Patient criteria that may change the course of treatment or treatment selection
    • Where does consensus exist, and where are more data needed?
  • Expansion of therapeutic CDK4/6 inhibition toward new indications, novel combinations, and additional breast tumor types

The symposium will be held at the Fontainebleau Miami Beach on March 12 from 7:00 am–8:30 am. Please join us live in Miami to learn the latest and greatest state-of-the-art science around CDK4/6 inhibitory therapies in ER+, HER-, metastatic breast cancer, as well as the most up-to-date information on appropriate and optimal use of these agents.

This will be the only independent CME-certified symposium focused entirely on CDK4/6 inhibitory therapy for metastatic breast cancer. You won’t want to miss this program!

Target Audience

This activity is intended for all attendees of the Miami Breast Cancer Conference® including medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Explain the mechanism of action of CDK 4/6 inhibition in the treatment of metastatic breast cancer
  • Discuss the role of emerging CDK4/6 inhibitory therapies in the treatment of metastatic breast cancer
  • Evaluate new and emerging clinical trial data that may change standards of care for patients with metastatic breast cancer
  • Identify strategies for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer

Co-Chairs

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Joyce O'Shaughnessy, MD
Chair, Breast Cancer Research
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide CME for physicians.

Physicians' Education Resource, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer.
 








Become a Member

Forgot Password?
Filter By